- Stage: Investment to support inflection point of rapid growth and commercial scale.
- Primary Focus: Life sciences and healthcare companies best positioned to drive or enable rapid transformation to next generation consumer demand and value impact driven healthcare 2021-2030. Key therapeutic areas include autoimmune rheumatic diseases and autoimmune neurological diseases, neuroinflammation, Long COVID.
- Company Attributes: Leadership position in dramatically under-served market; deep understanding of the industry ecosystem and competitive landscape; capacity to attract top talent across all disciplines; culture that embraces technology, data, innovation, and human capital and communication; prepared to scale quickly through operational excellence, acquisitions, partnerships, and/or licensing; commitment to strong governance; the Board, founder, officers, major investors aligned on operating plan and return objectives.
- Investment Approach: Lead or co-lead new investment round and serve on Board of Directors. Help de-risk final transition to major value and growth inflection point. Support parallel path to IPO or M&A.